𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Recurrence of Primary Sclerosing Cholangitis in Patients After Liver Transplantation

✍ Scribed by U. Ołdakowska-Jedynak; M. Nowak; K. Mucha; B. Foroncewicz; P. Nyckowski; K. Zieniewicz; B. Ziarkiewicz-Wróblewska; W. Patkowski; B. Górnicka; A. Paczkowska; B. Michałowicz; T. Pilecki; J. Pawlak; M. Krawczyk; L. Paczek

Book ID
116931996
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
68 KB
Volume
38
Category
Article
ISSN
0041-1345

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recurrence of primary sclerosing cholang
Recurrence of primary sclerosing cholangitis following liver transplantation
✍ Ivo W. Graziadei; Russell H. Wiesner; Kenneth P. Batts; Paul J. Marotta; Nichola 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 311 KB 👁 2 views

Recurrence of primary sclerosing cholangitis (PSC) following liver transplantation has been suggested; however, it has not been fully defined because of numerous complicating factors and the lack of diagnostic criteria. In the present study, we investigated the recurrence of PSC by developing strict

Risk factors for recurrence of primary s
Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation
✍ Evangelos Cholongitas; Vibhakorn Shusang; George V. Papatheodoridis; Laura Marel 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

Liver transplantation (LT) is the only therapeutic option for end-stage primary sclerosing cholangitis (PSC), but PSC can recur (rPSC) in some patients after LT. The aim of our study was to evaluate the risk factors associated with rPSC. Between 1989 and 2004, 69 patients receiving transplantation f

Risk factors for recurrence of primary s
Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation
✍ Jacob Alexander; James D. Lord; Matthew M. Yeh; Carlos Cuevas; Ramasamy Bakthava 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 2 views

Orthotopic liver transplantation (OLT) is the only effective treatment for end-stage liver disease due to primary sclerosing cholangitis (PSC). Recurrence of PSC has recently emerged as a leading cause of allograft failure in the long term. There is limited data on risk factors for recurrence of PSC